| |
Physicians, registered nurses, and mental health professionals are key agents to assess depression/distress and
intervene appropriately to provide physiological, psychological, and psychosocial care for the BMT population.
Several screening tools have been found to be effective in identifying distress and depression among BMT
patients. The Distress Thermometer is an initial screening tool which serves as a single question to identify
distress on a 1-10 scale. The distress is accompanied by 35 problem list prompting patient to identify their
problems in five different categories: practical, family, emotional, spiritual/religious, and physical (NCCN,
2010). Ransom, Jacobsen, & Booth-Jones (2006) validated and found the tool useful for measuring distress in
BMT patients. Scores greater than four or higher suggested a level of distress to have clinical significance.
Additional tools used to assess distress and depression include the Profile of Mood Scale (POMS), Symptom
Distress Scale (SDS), Beck Inventory of Depression (BID), Hospital Anxiety and Depression Scale (HADS), NCCN
Distress Thermometer, Zung Depression Inventory, Psychosocial Levels System (PLS), and Center for
Epidemiological Studies-Depression Scale (CES-D).
Psychosocial and coping status assessment is a continuation of the integral treatment of BMT treatment.
Assessment of psychological and coping status prior to BMT treatment has great importance in anticipating
difficulties and preventing emotional crises. Molassiotis (1999) found 25% patients had psychological
disturbances and impaired coping mechanisms during marrow transplantation. Additionally, impaired coping
mechanisms identified prior to BMT treatment were denial, lack of clarity, and ambiance over treatment. The
study found positive coping mechanisms during hospitalization were hope, directing attention, maintaining
control over situation, and acceptance. Ineffective verses effective coping mechanisms can have important
influences on psychological and physical outcomes. Previous studies have shown the importance of coping
assessment with BMT patient survival and positive health status (Andrykowski et al., 2005; Meyers et al., 1994;
Molassiotis, 1999; Wells, Booth-Jones, & Jacobsen, 2009). The assessment of coping styles enables
professionals to obtain the optimum level of adaptation to treatment and identifying and reinforcement specific
coping behaviors. The anticipation of specific psychosocial stressors may occur at various points in the
treatment process and to identify factors may contribute to the exacerbation of BMT distress. (Fife et al.,
2000) Coping assessment and evaluation should be performed after transplant and hospitalization as the patients
emotional and physical needs change (Wells et al., 2009). Educating effective coping and behavioral
strategies/programs can lower the incidence of distress and depression, improve coping, and enhance
psychological and physical well-being among the BMT patient population.
Psychosocial variables assessed before transplant have been shown to predict both psychosocial and physical
outcomes (Goetzmann et al., 2007). Social support has been an impact on survival rates following stem cell
transplant. Patients scoring a problematic social support prior to stem cell transplant showed a correspondence
with poorer survival (Frick et al., 2005) Patients with a high level of perceived social support had improved
survival (Colon et al, 1991) and higher quality of life (Frick et al., 2005; Rodrigue et al, 2000) The relation
between social support and positive health outcomes provides the emphasizes the importance of social support
assessment.
NCCN has clinical practice oncology guidelines, pathways, and protocols for recognizing, evaluating, and
treating psychological disturbances including distress, delirium, mood disorders, adjustment disorders,
anxiety, and personality disorders. The management of distress/depression should be based on a detailed
assessment of individual’s emotional, social, and psychological well-being with individualized interventions.
The individualized interventions may utilize several modalities including psychosocial therapy and
pharmacologic medication for symptom relief.
Psychosocial therapy includes, but not limited to, supportive psychotherapy, cognitive-behavioral therapy,
problem-solving techniques, and mindful-based therapy. Psychosocial therapy has been found to be effective for
cancer patients by improving the overall quality of life and reducing distress (Holland & Alici, 2010;
Jacobsen, 2009). Patients who received professional psychosocial therapy demonstrated significantly lower mood
disturbance during BMT treatment (Molassiotis, VanDen Akker, Milligan, Goldman, & Boughton, 1996).
Horton-Deutsch, Day, Haight, & Babin-Nelson (2007) conducted a pilot study to determine the acceptability
and feasibility using mindfulness based approaches for patients undergoing BMT to find participants had a more
positive affect after performing mindfulness interventions while experiencing an increase in symptoms, nausea,
and appetite problems. Gabriel et al. (2001) conducted an art therapy program, The Creative Journey, for BMT
patients to find art therapy strengthened positive thoughts, help resolve distressing emotional conflicts,
deepened awareness of spiritual issues, and facilitated communication with family. Although, no additional
studies were found using psychosocial interventions in the BMT patient population all recommended further
research in psychosocial therapy.
Bone marrow transplant patients are vulnerable to distress and depression at all stages in the process of
treatment. The management of distress/depression may benefit from a pharmacologic medication (antidepressant).
Williams & Dale (2006) reviewed six studies for the efficacy of antidepressant intervention and found
evidence to support antidepressants are effective in the reduction depression/depressing symptom in cancer
patients. The first line of depression treatment has been the usage of selective serotonin reuptake inhibitors
due to their efficacious and well tolerance. Several antidepressants classes are available including
tricyclics, serotonin-norephinephrine reuptake inhibitors, and norephinephrine-dopamine reuptake inhibitors.
The antidepressant selected should be based on the primary symptoms, patient’s prognosis, co-morbid conditions,
potential side effects and drug-drug interactions (Holland & Alici, 2010).
|
|
|